BlackRock Inc. boosted its position in shares of Puma Biotechnology Inc (NASDAQ:PBYI) by 31.4% in the fourth quarter, Holdings Channel reports. The firm owned 2,385,036 shares of the biopharmaceutical company’s stock after purchasing an additional 570,393 shares during the period. BlackRock Inc. owned about 0.06% of Puma Biotechnology worth $235,763,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently added to or reduced their stakes in the stock. Janus Henderson Group PLC boosted its position in Puma Biotechnology by 1.8% during the third quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock valued at $226,435,000 after purchasing an additional 33,270 shares during the last quarter. Perceptive Advisors LLC boosted its position in Puma Biotechnology by 26.0% during the third quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock valued at $110,627,000 after purchasing an additional 190,500 shares during the last quarter. Wells Fargo & Company MN boosted its position in Puma Biotechnology by 796.5% during the fourth quarter. Wells Fargo & Company MN now owns 524,933 shares of the biopharmaceutical company’s stock valued at $51,890,000 after purchasing an additional 466,382 shares during the last quarter. Point72 Asset Management L.P. boosted its position in Puma Biotechnology by 265.6% during the third quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock valued at $57,743,000 after purchasing an additional 350,300 shares during the last quarter. Finally, Emerald Advisers Inc. PA boosted its position in Puma Biotechnology by 8.8% during the fourth quarter. Emerald Advisers Inc. PA now owns 402,668 shares of the biopharmaceutical company’s stock valued at $39,804,000 after purchasing an additional 32,633 shares during the last quarter. 96.47% of the stock is owned by hedge funds and other institutional investors.

How to Become a New Pot Stock Millionaire

Shares of Puma Biotechnology Inc (NASDAQ PBYI) opened at $73.80 on Wednesday. Puma Biotechnology Inc has a 12-month low of $28.35 and a 12-month high of $136.90. The firm has a market capitalization of $2,730.00, a PE ratio of -9.39 and a beta of 0.26.

Puma Biotechnology (NASDAQ:PBYI) last announced its quarterly earnings results on Thursday, March 1st. The biopharmaceutical company reported ($1.71) earnings per share for the quarter, topping analysts’ consensus estimates of ($1.98) by $0.27. The company had revenue of $21.60 million during the quarter, compared to analyst estimates of $20.83 million. During the same period in the prior year, the firm earned ($1.22) EPS. equities research analysts predict that Puma Biotechnology Inc will post -3.86 earnings per share for the current fiscal year.

A number of analysts recently issued reports on the company. Credit Suisse Group set a $147.00 price objective on Puma Biotechnology and gave the company a “buy” rating in a research report on Monday, January 22nd. BidaskClub raised Puma Biotechnology from a “hold” rating to a “buy” rating in a research report on Saturday, February 17th. Citigroup reduced their price target on Puma Biotechnology from $164.00 to $146.00 and set a “buy” rating for the company in a research report on Wednesday, January 24th. Bank of America reduced their price target on Puma Biotechnology from $135.00 to $115.00 and set a “buy” rating for the company in a research report on Wednesday, January 24th. Finally, Barclays reduced their price target on Puma Biotechnology from $92.00 to $90.00 and set an “overweight” rating for the company in a research report on Friday, March 2nd. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and seven have given a buy rating to the company’s stock. The company currently has an average rating of “Buy” and a consensus price target of $103.11.

In other news, SVP Richard Paul Bryce sold 1,860 shares of Puma Biotechnology stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $172,515.00. Following the transaction, the senior vice president now directly owns 25,379 shares in the company, valued at $2,353,902.25. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Alan H. Auerbach sold 10,692 shares of Puma Biotechnology stock in a transaction dated Monday, January 22nd. The stock was sold at an average price of $92.75, for a total value of $991,683.00. Following the completion of the transaction, the insider now owns 4,155,931 shares in the company, valued at $385,462,600.25. The disclosure for this sale can be found here. Insiders own 21.10% of the company’s stock.

TRADEMARK VIOLATION NOTICE: This news story was originally reported by Daily Political and is owned by of Daily Political. If you are reading this news story on another website, it was stolen and reposted in violation of international copyright laws. The correct version of this news story can be read at https://www.dailypolitical.com/2018/03/14/blackrock-inc-grows-position-in-puma-biotechnology-inc-pbyi.html.

Puma Biotechnology Profile

Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.

Want to see what other hedge funds are holding PBYI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Puma Biotechnology Inc (NASDAQ:PBYI).

Institutional Ownership by Quarter for Puma Biotechnology (NASDAQ:PBYI)

Receive News & Ratings for Puma Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Puma Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.